Review Article

Purinergic signaling: A new front-line determinant of resistance and susceptibility in leishmaniasis

Mariana Chaves a, Luiz Eduardo Savio b,*, Robson Coutinho-Silva b,*

a Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

b Department of Cellular and Molecular Biology and Pathogenic Bio-Agents, University of São Paulo, Faculty of Medicine of Ribeirão Preto, São Paulo State, Brazil

ARTICLE INFO

Article history:
Received 18 April 2021
Accepted 17 June 2021
Available online 24 June 2021

Keywords:
Purinergic signaling
Leishmaniasis
Innate immune response
Evasion

ABSTRACT

Leishmaniasis is a neglected tropical disease that causes several clinical manifestations. Parasites of the genus Leishmania cause this disease. Spread across five continents, leishmaniasis is a particular public health problem in developing countries. Leishmania infects phagocytic cells such as macrophages, where it induces adenosine triphosphate (ATP) release at the time of infection. ATP activates purinergic receptors in the cell membranes of infected cells and promotes parasite control by inducing leukotriene B4 release and NLRP3 inflammasome activation. Moreover, uridine triphosphate induces ATP release, exacerbating the immune response. However, ATP may also undergo catalysis by ectonucleotidases present in the parasite membrane, generating adenosine, which activates P1 receptors and induces the production of anti-inflammatory molecules such as prostaglandin E2 and IL-10. These mechanisms culminate in Leishmania’s survival. Thus, how Leishmania handles extracellular nucleotides and the activation of purinergic receptors determines the control or the dissemination of the disease.

Leishmaniasis is a neglected tropical disease found in almost 100 countries worldwide. It affects 12 million people globally, and about 1.5–2 million new cases are reported annually [1,2]. Leishmaniasis is the second-leading cause of death related to parasite infections, causing 20,000 to 30,000 deaths per year [3]. This parasitic disease can be generated by at least 20 different protozoan species belonging to the family Trypanosomatidae, order Kinetoplastida, and genus Leishmania. Three clinical manifestations depend on the Leishmania species, ranging from self-healing cutaneous lesions and mucosal tissue damage to life-threatening visceral disease. Cutaneous leishmaniasis (CL) manifests primarily in the infectious site with self-resolving lesions; however, mucosal damage often occurs. In some cases,
more severe variants of CL may occur, including diffuse or disseminated CL [4]. Some Leishmania species may localize in nasal and oropharyngeal mucosa sites, where they cause mucocutaneous leishmaniasis. The parasites also can migrate to the spleen, liver, and bone marrow, leading to fatal visceral leishmaniasis (VL) [5].

Leishmania spp. are transmitted by the bite of female vectors called sand flies, genus Phlebotomus and Lutzomyia, transmitters of Old World and New World disease, respectively [2]. The parasites exist in two forms during their life cycle: flagellar promastigotes, found in the vector’s midgut, and amastigotes, mandatory intracellular forms found within phagolysosomes of phagocytic cells in the vertebrate host [6]. Infected sand flies bite the mammalian host during blood-feeding and regurgitate the infectious forms, called metacyclic promastigotes, into the dermis [7]. Leishmania parasites infect phagocytic cells present in the skin, mainly neutrophils and dermis-resident macrophages, in the first hour post-transmission [8]. The phagocytosed promastigote differentiates in amastigote form approximately 12–24 h later [9]. The Leishmania life cycle continues when the vector aspirates amastigote-infected cells or free parasites. Aflagellate amastigotes become virulent and non-proliferative metacyclic promastigotes in the vector’s digestive tract [10].

Currently, leishmaniasis treatment is a challenge for researchers and physicians. Researchers struggle to develop vaccines for humans and domestic reservoirs such as dogs. Medications for treating leishmaniasis are toxic and generate drug resistance [11]. Thus, new therapeutic strategies are vital for leishmaniasis management. In this effort, the elucidation of immune response is critical to the identification of new therapeutic targets.

Innate immune system cells present in the dermis, including dendritic cells (DC) and dermis-resident macrophages (DRMs), are the first line of defense against Leishmania [12,13]. After the infected vector injects the parasite into the dermis, neutrophils are quickly recruited to the infection site, promoting phagocytosis and becoming the first circulating cells to reach the infected tissue [9,14]. Recently, a population of DRMs was identified whose main characteristic is the expression of high levels of mannose receptor. In addition, these cells do not have progenitors from bone marrow, and IL-4 maintains them derived mainly from eosinophils in the skin. This inflammatory environment is required for DRM proliferation and maintenance of its M2-like phenotype [15,16]. DRMs are the first cells to become infected after transmission; they are the main target for infection and a niche for Leishmania major proliferation [9,15,17].

On the other hand, neutrophils can promote resistance to infection by some Leishmania species. During infection by Leishmania donovani, neutrophil depletion increased the parasitic burden in mice [18]. When obtained from Leishmania amazonensis-infected mice, neutrophils could release NETs, which helped prevent the parasite from spreading [19]. A previous study showed the importance of leukotriene B4 (LTB4) in the control of L. amazonensis infection [20]. Macrophages release LTB4 when infected with the parasites, and this mediator induces neutrophil recruitment [21,22]. The interaction between neutrophils and macrophages is relevant in the context of leishmaniasis. The essential role of neutrophils

Fig. 1 P2Y2 and P2X7 receptor cooperation favoring control of Leishmania infection. Leishmania infection induces P2Y2 and P2X7 overexpression. Extracellular ATP and UTP activate the P2Y2 receptor. The activation of the P2Y2 receptor potentiates ATP release via Panx-1 channels. High levels of ATP in the extracellular media culminate in activating the enzyme 5-LO and consequent LTB4 production and release. Then, LTB4 acts in the extracellular environment to activate the leukotriene B4 receptor 1 receptor that further induces NLRP3 activation and IL-1β secretion, promoting Leishmania infection control.
in the persistence of *L. major* infection is because these cells act as a “Trojan Horse.” In this model, neutrophils infected by *L. major* undergo apoptosis and silently enter macrophages, deactivating these cells [8,23] and favoring infection.

Macrophages and neutrophils have pattern recognition receptors (PRRs) activated by molecular patterns associated with pathogens (PAMPs) expressed on the *Leishmania* cell surface. The most well-known PAMPs present on *Leishmania* are lipophosphoglycan and glycoprotein 63, both in humans and mice [24–26]. One of the most well-known PRRs is Toll-like (TLR) receptors. The activation of TLRs was associated with the production and release of inflammatory mediators by macrophages and neutrophils, such as cytokines, lipid mediators, and adenosine 5’-triphosphate (ATP) [27,28].

ATP and other nucleotides are released through both specific and non-specific mechanisms [29]. Nucleotides may be released from live cells in a non-regulated pathway in response to various cell stress conditions, including exposure to cytotoxic agents, hypoxia, or plasma membrane damage [30]. During the inflammatory response, cell membrane disruption can lead to a non-specific release of large amounts of nucleotides. In the extracellular environment, ATP is practically non-existent; under physiological conditions, the extracellular ATP concentration is approximately 10 nM. By contrast, ATP is present in high concentrations in the intracellular space, ranging from 3 to 10 mM [31]. Ion channels in the cell surface, such as pannexin (Panx), may regulate ATP release in healthy cells and consequently participate in several physiologic and pathologic processes in various cell types and tissues [32]. Three forms of Panx have been described in vertebrates, including Panx1, expressed in various tissues and cells, Panx2 expressed in the central nervous system, and Panx3 primarily present in the skin and bone [33,34]. Interestingly, lipopolysaccharide was shown to induce ATP release via Panx in a TLR activation-dependent manner [35]. TLRs are also crucial to *Leishmania* infection [36], and we found that *L. amazonensis* phagocytosis by macrophages induced ATP secretion [22], suggesting possible participation of TLR in ATP release during *Leishmania* infection [Fig. 1].

When in the extracellular media, nucleotides are signaling molecules that activate P2 receptors. The low concentrations of ATP in the extracellular media are maintained by enzymes that rapidly metabolize ATP to adenosine, called ectonucleotidases. These enzymes consist of four large families of ectoenzymes that include ectonucleotide pyrophosphatase/phosphodiesterase, ectonucleoside triphosphate diphosphohydrolase (i.e., NTPDase1/CD39), alkaline phosphatases, and ecto-5’-nucleotidase (CD73) [37]. The adenosine formed by the action of these enzymes is known to activate P1 receptors [37].

The role of purinergic signaling in leishmaniasis has been explored over the last two decades [38–40]. Phagocytosis of *L. major* infection culminates in nucleotide release. *Leishmania* spp. is recognized by TLRs in the membrane of the host cell. The binding of parasites to these receptors induces ATP release to the extracellular environment through pannexin-1 channels. Once in the extracellular medium, ATP can be metabolized by ectonucleotidases such as ectonucleoside triphosphate diphosphohydrolase and ecto-5’-nucleotidase present in the *Leishmania* membrane, leading to Ado accumulation in the extracellular medium.

![Diagram](image-url)
amazonensis by macrophages induces the release of ATP into the extracellular space [22]. Once released, ATP and other nucleotides activate microbicidal mechanisms via P2 receptors. These nucleotides can also be degraded by ectoenzymes generating adenosine, which has anti-inflammatory effects. In this review, we discuss the role of purinergic signaling in leishmaniasis, highlighting mechanisms that contribute to parasite control and contribute to a better understanding of the infection physiology [see Fig. 2].

P2 receptors and leishmaniasis

The family of P2 receptors is expressed in almost all cells in the body [41]. This family of receptors is subdivided into P2X and P2Y. The P2Y receptor family includes metabotropic G-coupled protein receptors. These receptors have seven transmembrane domains [Fig. 1A], and eight members have been cloned in mammals: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14 [42]. P2Y receptors can be differentiated according to the type of G-coupled protein: while P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors bind to Gq protein, P2Y12, P2Y13, and P2Y14 receptors are linked to Gi protein. The P2Y11 receptor, on the other hand, can bind both Gq and Gs proteins, being the only one with this capacity [42]. The family of P2Y receptors triggers cellular events such as activation and differentiation of human pro-monocytic cells [43]. They also mediate the production of IL-8 in inflammatory bowel diseases [44]. Moreover, P2Y receptors are involved in chemotaxis and phagocytosis of macrophages [45,46], chemotaxis of neutrophils [47], and the clearance of damaged and apoptotic cells [48].

P2X are ionotropic receptors that form non-selective cationic channels permeable to Na+, K+, and Ca2+. Seven subtypes of the P2X family have been cloned: P2X1 to P2X7. The P2X5 receptor subtype is an exception, being permeable to Cl– [49]. The most studied of the P2X receptors is the P2X7 subtype. Their activation leads to the opening of non-selective pores in the cell membrane, allowing the passage of molecules up to 900 Da [50]. In addition, as a consequence of P2X7 receptor activation, several cellular mechanisms are triggered, including apoptosis, exosome release, and cytokine secretion (i.e., IL-1β and IL-18), along with inflammatory lipid mediators such as LTB4 [22,49,51]. P2X7 also triggers the activation of microbicidal mechanisms, including reactive oxygen species (ROS) and nitric oxide (NO) production [40]. Thus, the relevance of the P2X7 receptor in the control of several diseases caused by protozoan parasites has already been demonstrated [52]. Polymorphisms in the P2X7 receptor gene have also been associated with susceptibility to certain infectious diseases [53].

The importance of extracellular nucleotides and the activation of purinergic receptors during infection by Leishmania has been characterized [38,52]. ATP can lead to the elimination of L. amazonensis in infected macrophages via the P2X7 receptor, with an increased expression and functionality of this receptor during in vitro infection [54]. ATP controls L. amazonensis infection by activating the P2X7 receptor, which induces the release of LTB4 in peritoneal macrophages [22]. In addition, P2X7-deficient mice are more susceptible to L. amazonensis [22].
amazone infection [54]. The absence of P2X7 receptor during L. amazone infection resulted in higher IFN-γ and IL10 levels and lower IL-12p40, IL-4, IL-17, and TGF-β levels than in wild-type animals [54]. These data suggest that the lack of P2X7 receptors in L. amazone-infected mice causes intense inflammation associated with a Th1 response.

The P2X7 receptor is a well-known second signal for the full activation of inflammasome NLRP3, culminating in the conversion of pro-caspase-1 to its active form [53,54]. The caspase-1 enzyme is involved in the processing and release of cytokines such as IL-1β and IL-18, with subsequent systemic effects on the immune system. NLRP3 inflammasome assembly is essential for initiating and propagating inflammatory responses by activating macrophages, monocytes, and dendritic cells [55]. Moreover, inflammasome activation plays an essential role during intracellular protozoa infections, including leishmaniasis [56]. Lima-Junior and collaborators (2013) demonstrated the role of NLRP3 in inflammasome and NO production in the control of CI [57]. Furthermore, NLRP3 inflammasome and IL-1β have crucial roles in the virulence of L. donovani soon after transmission by the natural vector [58]. Based on these findings, several reports demonstrated the ability of Leishmania to inhibit or evade NLRP3 inflammasome expression and activation [59,60]. Recently, we found that L. amazone infection control via P2X7 receptor and LTB4 release depends on NLRP3 inflammasome and caspase-11 activation [61] [Fig. 3].

In addition to P2X receptors, P2Y2 and P2Y4 receptors are overexpressed and upregulated during infection. Urine triphosphate (UTP) in the extracellular media can induce apoptosis of infected macrophages and, consequently, eliminate the parasite [62]. The role of UTP was also described in vivo during L. amazone infection, shifting the immune responses to a Th1 profile and increasing host resistance via ROS production [59]. Subsequent studies revealed that P2Y2 and P2X7 receptors cooperate to trigger potent innate immune responses against L. amazone infection, which involves Panx-1 and LTB4 release [63] [Fig. 3]. Activation of P2Y receptor by UTP induced ATP release with consequent P2X7 receptor activation and NLRP3 inflammasome assembly [64].

### Ectonucleotidases and leishmaniasis

The ectonucleotidases play significant roles in nucleotide metabolism, preventing interaction of nucleotides with their receptors and consequent activation of the immune system and inflammation in mammals. NTPDases modulate ATP degradation. Several subtypes have already been described: NTPDase 1, 2, 3, and 8 are expressed on the cell surface, NTPDase 4, 5, 6, and 7 are located inside cells [65]. These enzymes possess different catalytic properties: NTPDase 1 or CD39 hydrolyzes ATP and adenosine diphosphate equally, while NTPDase 2, 3, and 8 have ATP as the preferable substrate [66].

CD73/ecto-5′-nucleotidase hydrolyzes 5′-adenosine monophosphate, generating adenosine (Ado) and inorganic phosphate [67]. Ado may be regulated by adenosine deaminase, which modulates adenosine levels by deaminating this nucleoside into inosine [37].

The principal member of the NTPDase family in mammals is CD39; its role is to limit ATP concentrations in the extracellular medium and catalysis of ATP to ADP and ADP to AMP, subsequently converted into Ado by CD73 [37]. Outside cells, Ado has a half-life of a few seconds and can activate P1 purinergic receptors [39]. In humans, CD39 and CD73 are constitutively expressed in innate and adaptive immune cells such as monocytes, granulocytes, B-cells, and T-cell subsets [70]; it activates predominantly anti-inflammatory responses.

However, NTPDases were not described only in mammals. Several species of Trypanosomatides, including Leishmania, including Leishmania infantum, Leishmania braziliensis, L. donovani, Leishmania mexicana, L. major, L. amazone, and Leishmaniasis tropica, express two predicted NTPDases [71,72]. Ecto-ATPase activity was demonstrated in L. amazone, L. tropica, and L. infantum [72–74] [Fig. 1].

L. amazone infection increases the number of CD39+ CD73+ DC with consequent deactivation of these cells, promoting the establishment of the disease [75]. In L. donovani and L. infantum infections, ectonucleotidase inhibition in host cells decreased parasite survival and increased host-favorable cytokine production [76,77]. These findings demonstrated the role of these enzymes in Leishmania infection pathophysiology. These findings also corroborate the observation that patients with VL showed higher serum Ado levels than healthy individuals [78], suggesting that Ado is an essential regulator in VL.

Moreover, sandfly saliva exhibits ATPase activity which can hydrolyze ATP [79]. This saliva possesses high levels of Ado which modulates the inflammatory microenvironment in the skin, causing NO inhibition and macrophage inactivation.

---

**Table 1: Adenosine receptor signaling and leishmaniasis.**

| Adenosine receptor | G-coupled protein | Second messengers | Effector enzymes | Effect in leishmaniasis |
|--------------------|-------------------|------------------|------------------|------------------------|
| A$_{2a}$           | Gs                 | cAMP†            | PKA              | Favors leishmaniasis [80] |
| A$_{2b}$           | Gs                 | cAMP†            | PKA              | Favors leishmaniasis [80] |
| P2Y2               | Gq                 | IP$_3$ + DG      | PKC              | Unknown                |
| A$_4$              | Gi                 | cAMP↓            | PKA              | Unknown                |
| P2X7               | Gq                 | IP$_3$ + DG      | PKC              | Unknown                |

Abbreviations: PLC: Phospholipase C; IP3: Inositol 1,4,5-trisphosphate; DG: Diacylglycerol; PKA: Protein kinase A; PKC: Protein kinase C; Ø: inhibition.
consequently favoring parasitic growth in host cells such as macrophages and neutrophils [80,81].

P1 receptors and leishmaniasis

Ado is an agonist for the P1 receptor family that includes four metabotropic receptors. All are G-coupled protein receptors, named A1, A2A, A2B, and A3 [82]. Depending on the type of G-protein, these receptors are coupled and can generate inhibitory or stimulatory effects concerning the production of cyclic AMP (cAMP). The activation of A1 and A3 has inhibitory effects via G{i,2} and G{i,2} proteins, respectively. By contrast, A2A and A2B receptors stimulate cAMP production and activate adenylyl cyclase via G{i,2} and G{i,2} respectively [82,83]. Moreover, the activation of A2A receptors may also induce phospholipase C activation via G{i,2} [83] [Table 1]. In general, the activation of P1 receptors can generate several effects, including inflammatory reactions [83,84].

Ado possesses immunosuppressive properties; it suppresses M1 macrophage functions and favors polarization to the M2 phenotype [85]. In addition, the activation of Ado receptors may impair the differentiation of monocytes into macrophages [86].

Macrophages produce nitric NO through inducible NO synthase (iNOS) with an anti-leishmanial effect [87]. Interestingly, Ado can negatively regulate the release of NO by impairing the expression of iNOS [88]. Moreover, A2B receptor signaling prevents IFN-γ production by Th1 cells and, consequently, IFNγ-induced macrophage activation [89]. L. infantum can subvert the host response by inducing A2A receptor signaling to promote the establishment of the infection [90] [Fig. 3]. Moreover, A2B receptor activation can impair DC activation [91]. The anti-inflammatory effects of PGs have been demonstrated during the resolution phase of inflammation [92] [Fig. 3]. PGE2 suppresses macrophage inflammatory responses and allows Leishmania establishment [93,94]. PGE2 impairs nitric oxide synthase expression and, consequently, downregulates NO production [92,95], combining with PGE2 to favor infection [Fig. 3]. These findings suggest that Ado may induce the formation of an anti-inflammatory environment that facilitates the parasite growth and consequent establishment of infection.

Conclusion

In summary, studies of purinergic signaling during Leishmania infection are crucial for understanding the disease’s resistance and susceptibility. Consequently, new therapeutic methods could be developed using these mechanisms. As described here, the parasites have developed strategies to evade control pathways. The host triggers the purinergic signaling as an attempt to eradicate the parasite. P2 receptors, when activated during infection, stimulate the production and release of several microbicidal molecules. However, to perpetuate itself, Leishmania built pathways that can prevent its death, using purinergic mechanisms such as ectonucleotidase overexpression and P1 receptor activation.

In this context, the development or discovery of specific P2Y2 or P2X7 agonists could contribute to parasite control boosting the immune response in leishmaniasis. Interestingly, natural compounds have been explored as modulators of P2 receptors [96,97]. Clemastine fumarate, a synthetic ethanalamine that potentially acts as a P2X7 receptor positive allosteric modulator, showed antileishmanial effects [98]. Diquafosol (INS365), a P2Y2 agonist, has already been approved as a topical treatment for dry-eye disease could be repurposed for cutaneous leishmaniasis treatment [99]. In addition to P2 agonists, the administration of CD39/CD73 inhibitors or neutralizing antibodies that limit adenosine generation could also be an interesting approach to inhibit parasite growth in host cells [70]. Finally, adenosine A2A and A2B antagonists could also inhibit the formation of an immunosuppressive environment that contributes to parasite spreading, as previously proposed for the treatment of some types of cancer [70].

Development of more severe forms of leishmaniasis and even asymptomatic disease may be caused by host defect in the signaling triggered by the purinergic receptor; nevertheless, this has not yet been demonstrated in Leishmania-infected patients and would be of great importance for understanding the disease and its worsening. Such processes have been shown to occur in other infections, such as Mycobacterium tuberculosis that causes tuberculosis [53].

Conflicts of interest

The authors declare no competing or financial interests.

Acknowledgments

This work was supported by funds from the Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP (2018/14398-0), Conselho Nacional de Desenvolvimento Científico e Tecnológico do Brasil – CNPq (306839/2019-9) RCS and (305857/2020-7) LEBS. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro - FAPERJ (E-26/202.701/2019 and E-26/010.002260/2019 to LEBS, E-26/010.002985/2014, E-26/010.101036/2018 and E-26/202.774/2018 to RCS).

REFERENCES

[1] Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet 2018;392:951–70.
[2] Steverding D. The history of leishmaniasis. Parasites Vectors 2017;10:82.
[3] Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, Reed SG. Case study for a vaccine against leishmaniasis. Vaccine 2013;31:B244–9.
[4] van Griensven J, Carrillo E, Lopez-Velez R, Lynen L, Moreno J. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect 2014;20:286–99.
[5] Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005;366:1561–77.
granulocyte serves as a vector for Leishmania entry into macrophages. J Immunol 2004;173:6521–5.
[24] Isnard A, Shio MT, Olivier M. Impact of Leishmania metalloprotease GP63 on macrophage signaling. Front Cell Infect Microbiol 2012;2:72.
[25] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373–84.
[26] Sperth GF, Garraway LA, Turco SJ, Beverley SM. The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc Natl Acad Sci U S A 2003;100:9536–41.
[27] Cohen P. The TLR and IL-1 signalling network at a glance. J Cell Sci 2014;127:2383–90.
[28] Ren H, Teng Y, Tan B, Zhang X, Jiang W, Liu M, et al. Toll-like receptor-triggered calcium mobilization protects mice against bacterial infection through extracellular ATP release. Infect Immun 2014;82:5076–85.
[29] Dosch M, Gerber J, Jebbawi F, Beldi G. Mechanisms of ATP release by inflammatory cells. Int J Mol Sci 2018;19:1222.
[30] Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 2014;21:79–91.
[31] Trautmann A. Extracellular ATP in the immune system: more than just a “danger signal”. Sci Signal 2009;2:p6.
[32] Dahl G. ATP release through pannexon channels. Philos Trans R Soc Lond B Biol Sci 2015;370:20140191.
[33] Baranova A, Ivanov D, Petrush N, Pestova A, Skoblov M, Kelmanison I, et al. The mammalian pannexin family is homologous to the invertebrate innexin gap junction proteins. Genomics 2004;83:706–16.
[34] Bruzzone R, Hormuzdi SG, Barbe MT, Herb A, Monyer H. Pannexins, a family of gap junction proteins expressed in brain. Proc Natl Acad Sci U S A 2003;100:13644–9.
[35] Silberfeld A, Chavez B, Obidike C, Daugherty S, de Groat WC, Beckel JM. LPS-mediated release of ATP from urothelial cells occurs by lysosomal exocytosis. Neurourol Urodyn 2020;39:1321–9.
[36] Halliday A, Bates PA, Chance ML, Taylor MJ. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan. Parasites Vectors 2016;9:489.
[37] Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008;1783:673–83.
[38] Chaves MM, Canetti C, Coutinho-Silva R. Crosstalk between purinergic receptors and lipid mediators in leishmaniasis. Parasites Vectors 2016;9:489.
[39] Marques-da-Silva C, Chaves MM, Thorstenberg ML, Figliuolo VR, Vieira FS, Chaves SP, et al. Intralethal uridine-5’-triphosphate (UTP) treatment induced resistance to Leishmania amazonensis infection by boosting Th1 immune responses and reactive oxygen species production. Purinergic Signal 2018;14:201–11.
[40] Coutinho-Silva R, Savio LEB. Purinergic signalling in host innate immune defence against intracellular pathogens. Biochem Pharmacol 2021;187:114405.
[41] Burnstock G. Purine and pyrimidine receptors. Cell Mol Life Sci 2007;64:1471–83.
[42] Jacobson KA, Delicado EG, Gachet C, Kennedy C, von Krugh B, Garrad RC, et al. Update of P2Y receptor pharmacology: IUPHAR Review 27. Br J Pharmacol 2021;187:114405.
Desensitization and coupling to mitogen-activated protein kinases. J Cell Physiol 2001;187:196–208.

Khine AA, Del Sorbo L, Vascotto R, Vogli S, Tullis E, Slutsky AS, et al. Human neutrophil peptides induce interleukin-8 production through the P2Y6 signaling pathway. Blood 2006;107:2936–42.

Kronlage M, Song J, Sorokin L, Isfort K, Schwerdtle T, Leipziger J, et al. Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. Sci Signal 2010;3:ra45.

Koizumi S, Shimogoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K, Tsuda M, et al. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 2007;446:1091–5.

Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, North RA. Molecular physiology of P2X receptors. Physiol Rev 2002;82:1013–67.

Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Coutinho-Silva R, Persechini PM. P2Z purinoceptor-mediated apoptosis in J774 cells. Am J Physiol Cell Physiol 2004;286:C1100–8.

Wittmann J,条件文中に含まれる文を記載

Coutinho-Silva R, Persechini PM. P2Z purinoceptor-associated proteins induced by extracellular ATP in macrophages and J774 cells. Am J Physiol 1997;273:C1793–800.

Savio VR, de Andrade Mello P, da Silva CG, Coutinho-Silva R. The P2X7 receptor in inflammatory diseases: effect on tolerogenicity of the P2X7 receptor in murine cutaneous leishmaniasis: aspects of inflammation and parasite control. Purinergic Signal 2017;13:143–52.

Kahlenberg JM, Dubyak GR. Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am J Physiol Cell Physiol 2004;286:C1100–8.

Marinho Y, Marques-da-Silva C, Santana PT, Chaves MM, Chaves SP, Figliuolo VR, Thorstenberg MLP, Martins MDA. Mg-dependent ecto-ATPase activity in Leishmania tropica. Arch Biochem Biophys 1997;341:40–5.

Sutterwala FS, Ogura Y, Zamboni DS, Roy CR, Flavell RA. Leishmania amazonensis upregulates purinergic receptor expression and induces cell-cell susceptibility to UTP-mediated apoptosis. Cell Microbiol 2011;13:1410–28.

Thorstenberg ML, Rangel Ferreira VM, Amorim N, Canetti C, Morrone FB, Alves Filho JC, et al. Purinergic cooperation between P2Y2 and P2X7 receptors promotes cutaneous leishmaniasis control: involvement of pannexin-1 and leukotrienes. Front Immunol 2018;9:1531.

Marques-da-Silva C, Chaves MM, Chaves SP, Figliuolo VR, Meyer-Fernandes JR, Corte-Real S, et al. Infection with Leishmania amazonensis upregulates purinergic receptor expression and induces host-cell susceptibility to UTP-mediated apoptosis. Cell Microbiol 2011;13:1410–28.

Vieira DP, Paletta-Silva R, Saraiva EM, Lopes AH, Meyer-Fernandes JR, Duarte PM, Rodrigues CO, Saad-Nehme J, Lopes AH. Mg-dependent ecto-ATPase activity in Leishmania tropica. Arch Biochem Biophys 1997;341:40–5.

Peacock CS, Seeger K, Harris D, Murphy L, Ruiz JC, Quail MA, et al. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat Genet 2007;39:839–47.

Pinheiro CM, Martins-Duarte ES, Ferraro RB, Fonseca de Souza AL, Gomes MT, Lopes AH, et al. Leishmania amazonensis: biological and biochemical characterization of ecto-nucleoside triphosphate diphosphohydrolase activities. Purinergic Signal 2019;6:209–30.

Vieira DP, Paletta-Silva R, Saraiva EM, Lopes AH, Meyer-Fernandes JR. Leishmania chagasi: an ecto-3'-nucleotidase activity mediated by inorganic phosphate and its possible involvement in parasite-macrophage interaction. Exp Parasitol 2011;127:702–7.

Figueiredo AB, Serafim TD, Marques-da-Silva EA, Meyer-Fernandes JR, Afonso LC. Leishmania amazonensis impairs DC function by inhibiting CD40 expression via A2B adenosine receptor activation. Eur J Immunol 2012;42:1203–15.

Basu M, Gupta P, Dutta A, Jana K, Ukil A. Increased host ATP efflux and its conversion to extracellular adenosine is crucial for establishing Leishmania infection. J Cell Sci 2020;133:jcs239939.

Peres NT, Cunha LCS, Barbosa MLA, Santos MB, de Oliveira FA, de Jesus AMR, et al. Infection of human...
macrophages by Leishmania infantum is influenced by ectonucleotidases. Front Immunol 2017;8:1954.

[78] Rai AK, Thakur CP, Velpandian T, Sharma SK, Ghosh B, Mitra DK. High concentration of adenosine in human visceral leishmaniasis despite increased ADA and decreased CD73. Parasite Immunol 2011;33:632–6.

[79] Charlab R, Valenzuela JG, Rowton ED, Ribeiro JM. Toward an understanding of the biochemical and pharmacological complexity of the saliva of a hematophagous sand fly Lutzomyia longipalpis. Proc Natl Acad Sci U S A 1999;96:15155–60.

[80] Katz O, Waitumbi JN, Zer R, Warburg A. Adenosine, AMP, and protein phosphatase activity in sandfly saliva. Am J Trop Med Hyg 2000;62:145–50.

[81] Carregaro V, Ribeiro JM, Valenzuela JG, Souza-Junior DL, Costa DL, Oliveira CJ, et al. Nucleosides present on phlebotomine saliva induce immunosuppression and promote the infection establishment. PLoS Neglected Trop Dis 2015;9:e0003600.

[82] Fredholm BB, Irenius E, Kull B, Schulte G. Comparison of Adenosine receptors expressed in Chinese hamster ovary cells11Abbreviations: cAMP, cyclic adenosine 3’,5’-monophosphate; CHO, Chinese hamster ovary; NBMPR, nitrobenzylthioinosine; and NECA, 5’-N-ethylcarboxamido adenosine. Biochem Pharmacol 2001;61:443–8.

[83] Antonioli L, Fornai M, Blandizzi C, Pacher P, Hasko G. Adenosine signaling and the immune system: when a lot could be too much. Immunol Lett 2019;205:9–14.

[84] Gessi S, Merighi S, Varani K, Borea PA. Adenosine receptors and its derivatives control human monocyte differentiation into highly accessory cells versus macrophages. J Leukoc Biol 1990;47:429–39.

[85] Mukbel RM, Petersen C, Ghosh M, Gibson K, Patten C, Jones DE. Macrophage killing of Leishmania amazonensis amastigotes requires both nitric oxide and superoxide. Am J Trop Med Hyg 2007;76:669–75.

[86] Xaus J, Mirabet M, Lloberas J, Soler C, Lluis C, Franco R, et al. IFN-γ up-regulates the A(2B) adenosine receptor expression in macrophages: a mechanism of macrophage deactivation. J Immunol 1999;162:3607–14.

[87] Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996;157:4634–40.

[88] Lima MHF, Sacramento LA, Quirino GFS, Ferreira MD, Benevides L, Santana AKM, et al. Leishmania infantum parasites subvert the host inflammatory response through the adenosine A2A receptor to promote the establishment of infection. Front Immunol 2017;8:815.

[89] Figueiredo AB, Souza-Testasica MC, Mineo TWP. Lutzomyia longipalpis. Proc Natl Acad Sci U S A 2011;33:632–7.